COX

4-Methylamino antipyrine is a COX inhibitor derived from the active metabolite of Metamizole, a pyrazolone non-steroidal anti-inflammatory drug (NSAID). It exhibits analgesic and antipyretic activities, making it beneficial for alleviating pain and reducing fever. Although its anti-inflammatory properties are relatively weak, 4-Methylamino antipyrine serves as a valuable tool in pharmacological studies involving pain management and inflammatory responses.

α-Chaconine is an inhibitor of COX-2 and iNOS, which demonstrates significant anti-inflammatory activity. It effectively reduces the transcriptional expression of COX-2, IL-1β, IL-6, and TNF-α. Additionally, α-Chaconine suppresses LPS-induced expression of iNOS and COX-2 at both the protein and mRNA levels, along with their promoter activities in RAW 264.7 macrophages. This makes α-Chaconine a valuable reagent for studies focused on inflammation and related signaling pathways.

Sphondin is a cyclooxygenase (COX) inhibitor that effectively reduces the levels of COX-2 protein and prostaglandin E2 (PGE2) release in A549 cells stimulated by IL-1β. This compound's anti-inflammatory properties make it a valuable tool for research into COX-related pathways and the modulation of inflammatory responses in various cellular models. Sphondin can facilitate investigations into therapeutic strategies for inflammatory diseases.

FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), exhibiting IC50 values of 3.5 μM and 3.1 μM, respectively, in RBL-1 cells. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its dual inhibition of leukotriene and prostaglandin synthesis positions FPL 62064 as a pertinent reagent for studies focusing on inflammation and related therapeutic interventions.

Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that functions as an inhibitor of secretory phospholipase A2 (sPLA2) and cyclooxygenase-2 (COX-2). This compound exhibits potent anti-inflammatory activity, making it useful in research focused on inflammation and pain modulation. Its dual mechanism of action presents opportunities for investigating pathways involved in inflammatory diseases and related therapeutic interventions.

Pelubiprofen is an orally active anti-inflammatory agent that inhibits cyclooxygenase (COX) enzyme activity, displaying IC50 values of 10.66 μM for COX-1 and 2.88 μM for COX-2. It demonstrates notable anti-inflammatory and analgesic properties, making it valuable for research in pain management and inflammation pathways. Pelubiprofen can be utilized in studies examining the roles of COX enzymes in various biological processes and diseases.

Ketorolac-d5 is a deuterated form of Ketorolac, a non-steroidal anti-inflammatory drug that functions as a nonselective inhibitor of cyclooxygenase (COX). It displays inhibitory potency with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is widely utilized in pharmacological studies to investigate the biochemical pathways of pain and inflammation, as well as in drug metabolism and pharmacokinetic research.

EXP3179 is a selective cyclooxygenase-2 (COX-2) inhibitor, notably an intermediate aldehyde metabolite of Losartan. It effectively reduces the expression of COX-2 in endothelial cells, leading to significant anti-inflammatory effects. This compound is useful in research applications focused on inflammation and related signaling pathways.

10,12-Tricosadiynoic acid is a selective and potent inhibitor of acyl-CoA oxidase-1 (ACOX1). It demonstrates significant potential in addressing metabolic disorders induced by high-fat diets or obesity by enhancing mitochondrial lipid metabolism and modulating reactive oxygen species (ROS) levels. Additionally, this compound serves as a versatile click chemistry reagent, featuring an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it valuable for various biochemical applications.

LY256548 is a potent inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and cyclooxygenase (COX), demonstrating significant anti-ischemic and anti-inflammatory properties. This compound effectively reduces leukotriene B4 production in response to A23187 stimulation. In preclinical models, LY256548 has shown efficacy in mitigating bone damage and paw swelling in rat models of Freund's complete adjuvant-induced arthritis (FCA), making it a valuable tool for research into inflammatory diseases and analgesic mechanisms.

FR122047 (hydrochloride) is a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 value of 28 nM. This compound exhibits antiplatelet, analgesic, and anti-inflammatory activities, making it a valuable tool for research in the fields of pain management and cardiovascular studies. Its ability to modulate COX-1 offers insights into the therapeutic targeting of inflammatory pathways.

Zaltoprofen is a non-steroidal anti-inflammatory drug (NSAID) that acts as a preferential inhibitor of cyclooxygenase-2 (COX-2), exhibiting IC50 values of 1.3 μM for COX-1 and 0.34 μM for COX-2. It demonstrates significant anti-inflammatory and analgesic properties, making it beneficial for the management of inflammatory pain. Zaltoprofen is utilized in research settings to explore mechanisms of inflammation and pain pathways.

6-Methoxy-2-naphthoic acid is a potent inhibitor of COX-1 and COX-2 enzymes. It effectively inhibits the synthesis of gastric mucosal prostaglandin E2, making it relevant in studies related to inflammation and pain-related conditions. Additionally, 6-Methoxy-2-naphthoic acid serves as an impurity in Naproxen and can be utilized in the synthesis of various active compounds, contributing to diverse research applications in pharmaceutical development.

Parecoxib Sodium is a selective COX-2 inhibitor that effectively penetrates the blood-brain barrier and serves as a proagent for Valdecoxib. This nonsteroidal anti-inflammatory drug (NSAID) inhibits prostaglandin synthesis, making it suitable for the relief of acute postoperative pain as well as for managing symptoms associated with chronic inflammatory conditions, including osteoarthritis and rheumatoid arthritis. It has important applications in both clinical and preclinical research focused on pain management and inflammation.

Tolmetin sodium dihydrate is a potent non-steroidal anti-inflammatory drug (NSAID) that primarily targets cyclooxygenase (COX) enzymes, exhibiting IC50 values of 0.35 μM for human COX-1 and 0.82 μM for COX-2. This compound is commonly utilized in research related to inflammation and pain modulation. Its ability to effectively inhibit COX activity makes it valuable for studying various inflammatory pathways and developing new therapeutic strategies in pain management.

Hamaudol is a chromone derived from Saposhnikovia divaricata, acting as a potent inhibitor of cyclooxygenase (COX)-1 and COX-2, with IC50 values of 0.30 mM and 0.57 mM, respectively. This compound exhibits significant analgesic and anti-inflammatory properties, making it a valuable tool in research focused on pain relief and inflammation modulation. Hamaudol is suitable for investigations into COX inhibition and related biological pathways.

Methylhydroquinone is a potent COX inhibitor with noted activity against ovine COX-1 and human recombinant COX-2, exhibiting IC50 values of 480.7 μM and 52.2 μM, respectively. This compound demonstrates anti-inflammatory properties primarily through the inhibition of prostaglandin synthesis. Additionally, it has been associated with potential DNA-damaging effects, including the induction of DNA single-strand breaks. Methylhydroquinone functions by competitively binding to the active sites of COX-1, engaging in non-covalent interactions to exert its biological activities.